<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832180</url>
  </required_header>
  <id_info>
    <org_study_id>IM006-032</org_study_id>
    <nct_id>NCT02832180</nct_id>
  </id_info>
  <brief_title>The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects</brief_title>
  <official_title>The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, 2-cycle, multiple-dose, single-sequence study in women of&#xD;
      child-bearing potential. The primary objective is to assess the effect of BMS-986142 on the&#xD;
      pharmacokinetics (PK) of Combined Oral Contraceptive Containing Ethinyl Estradiol and&#xD;
      Norethindrone Acetate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of EE and NET</measure>
    <time_frame>Cycle 1 Day 21 to Cycle 2 Day 22 (30 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of EE and NET</measure>
    <time_frame>Cycle 1 Day 21 to Cycle 2 Day 22 (30 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve over the dosing interval [AUC (TAU)] of EE and NET</measure>
    <time_frame>Cycle 1 Day 21 to Cycle 2 Day 22 (30 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and death.</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 2 Day 25; For SAEs up to 30 days post discontinuation of dosing or participation.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Daily single dose of OC containing EE and NET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily single dose of OC Containing EE and NET alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily single dose of OC in combination with BMS-986142</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily single dose of OC containing EE and NET in combination with BMS-986142.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC containing EE and NET</intervention_name>
    <arm_group_label>Daily single dose of OC containing EE and NET</arm_group_label>
    <arm_group_label>Daily single dose of OC in combination with BMS-986142</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986142</intervention_name>
    <arm_group_label>Daily single dose of OC in combination with BMS-986142</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Target population: Healthy females with no clinically significant deviations from&#xD;
             normal in medical history, physical examinations, vital signs, electrocardiograms&#xD;
             (ECGs), physical measurements, and clinical laboratory tests that are willing to&#xD;
             switch to Loestrin during the study.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18 to 32 kg/m2.&#xD;
&#xD;
          -  Women of childbearing potential with intact ovarian function and history of regular&#xD;
             menstrual cycles must have been on a stable regimen of combination of birth control&#xD;
             containing ethinyl estradiol without evidence of clinically significant breakthrough&#xD;
             bleeding or spotting for at least 2 consecutive months prior to Day -1.&#xD;
&#xD;
          -  Women of childbearing potential must agree to follow instructions for method(s) of&#xD;
             contraception for the duration of treatment with study drugs (53 days) plus 5&#xD;
             half-lives of BMS-986142 (3 days) plus 30 days (duration of ovulatory cycle) for a&#xD;
             total of 86 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any chronic or acute illness including active TB in the last 3 years,&#xD;
             recent infection, gastrointestinal disease, smoking within less than 6 months prior to&#xD;
             dosing, alcohol abuse, inability to tolerate oral medication, or inability to be&#xD;
             venipunctured.&#xD;
&#xD;
          -  History of jaundice or irregular bleeding associated with taking oral contraceptives,&#xD;
             frequent headaches, cerebrovascular or coronary-artery disease, retinal vascular&#xD;
             lesions, cancer of the breast or endometrium, deep venous thrombosis, pulmonary&#xD;
             embolism, stroke, transient ischemic attack, or phlebitis.&#xD;
&#xD;
          -  Vaccination or plans for vaccination with any live vaccine 12 weeks prior to first&#xD;
             dose of study drug, during the course of the study, or 30 days after the last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs, electrocardiograms, or clinical laboratory&#xD;
             determinations beyond what is consistent with the target population.&#xD;
&#xD;
          -  History of allergies and adverse drug reaction to any oral contraceptive compounds or&#xD;
             Bruton tyrosine kinase (BTK) inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Evansville Clinical Research Unit</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/pages/home.aspx</url>
    <description>BMS Clinical Trial Education Resource</description>
  </link>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

